1st Quarter - Report

BIOMARIN PHARMACEUTICAL INC. for BIOMARIN PHARMACEUTICAL INC.

Firm
Client
Income
—
Expenses
$530,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Tariff (miscellaneous tariff bills) TAR

GENERAL DISCUSSIONS REGARDING SECTION 232 INVESTIGATION ON BIOPHARMACEUTICALS

LobbyistCovered position, as disclosed
JOHN EDWARD GREISSING —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

GENERAL DISCUSSIONS REGARDING GENETIC TESTING AND NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION GENERAL DISCUSSIONS RELATED TO TARIFFS ON PHARMACEUTICALS GENERAL DISCUSSIONS RELATED TO METABOLIC DISORDER PUBLIC HEALTH CAMPAIGN GENERAL DISCUSSIONS RELATED TO RARE DISEASE DRUG DEVELOPMENT

LobbyistCovered position, as disclosed
JOHN EDWARD GREISSING —
KATHRYN LOWELL —

Contacted: Food & Drug Administration (FDA); Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION

LobbyistCovered position, as disclosed
JOHN EDWARD GREISSING —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.